Infliximab and Anti-Infliximab Ab infliximab

Synonyms

Allscripts (AEHR) Order Name

Not Orderable

Sunrise Clinical Manager (SCM) Order Name

Not Orderable

Clinical Info

Provides infliximab drug concentration levels as well as levels of anti-infliximab antibodies.
 
 
In the absence of anti-infliximab antibodies, the infliximab drug level typically reflects the total infliximab concentration in serum. In the presence of anti-infliximab antibodies, the infliximab drug level typically reflects the antibody-unbound fraction of infliximab concentration in serum. The presence of infliximab drug, even at concentrations well above target treatment levels (>50 μg/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rhematoid arthritis, or other autoimmune conditions.
 
Test has been inactivated
please order ANSERIFX

Specimen Type

Container

Collection Instructions

Container/Tube: Gold top or Red top tube
Specimen: 2 ml serum (1 mL min- does not allow for repeat testing)
Transport Temperature: Refrigerated
Stability: 7 Days Room Temperature
                 7 Days Refrigerated
                 359 Days Frozen
 
Note: Serum must be separated from cells within 45 minutes of venipuncture

Transport Instructions

Refrigerated

Specimen Stability

7 Days Room Temperature
                 7 Days Refrigerated
                 359 Days Frozen
 
Note: Serum must be separated from cells within 45 minutes of venipuncture

Methodology

Electrochemiluminescence immunoassay (ECLIA)

Days Performed

Performing Laboratory

LabCorp of America

CPT

80299
82397

PDM

Result Interpretation

 

Infliximab drug level:	<0.4 µg/mL
• Result ≥0.4 µg/mL indicates detection of infliximab.
• In the presence of anti-infliximab antibodies, the infliximab drug level reflects the antibody-unbound fraction of infliximab concentration in serum.
Anti-infliximab antibody:	<22 ng/mL
• Result ≥22 ng/mL indicates detection of anti-infliximab antibodies.

 

Forms